Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Venn lands €3.4mln contract with US biotech

The contract research group, which provides clinical trial management and resourcing for the drugs industry, has struck the deal with an unnamed by leading US-based biotechnology client.
Venn lands €3.4mln contract with US biotech
Companies outsource clinical trials to Venn.

The current year is already shaping up to be a good one for Venn Life Sciences (LON:VENN), though the foundation work for today’s €3.4mln order was done in 2015, the company said.

The contract research group, which provides clinical trial management and resourcing for the drugs industry, has struck the deal with an unnamed by leading US-based biotechnology client.

The work is an extension to an existing phase II clinical trial, so it will start immediately and run to the end of 2017.

Venn chief Tony Richardson said: "During 2015, I commented that executing our work to a consistent high standard would bring significant rewards and I am delighted to be able to show the concrete evidence of this.

“This is the second extension of what is a complex international programme and this endorsement is well deserved by our team. It is particularly pleasing to win this business at the commencement of the new year. 2015 was a year of significant growth at Venn and new business wins of this magnitude will enable us to continue expanding our business."    

On Friday the company told investors that it expects revenues for 2015 to be at least double the prior year.

It highlighted that it has won enterprise level contracts and has grown its reputation for excellence.

Venn also said it ended December with €3.4mln of cash. The business was now generating free cash flows, and was well funded for future growth, it added.

Ian_55ae0ddd437b7.jpg
Why Invest In Venn Life Sciences Holdings plc? Read More Here

Register here to be notified of future VENN Company articles
View full VENN profile

Venn Life Sciences Holdings plc Timeline

Big Picture
March 22 2017
Newswire
November 02 2016

Related Articles

Cynata-CEO-Dr-Ross-Macdonald-presenting-Syd-Mar-2017.jpg
March 16 2017
Dr Ross Macdonald talked stemcell research with investors.
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use